Jacobson Pharma and JBM Renew Connected-Party Framework Deals to 2029

Jacobson Pharma Corporation Limited ( (HK:2633) ) just unveiled an update.

Jacobson Pharma and JBM (Healthcare) have renewed a set of framework agreements governing their continuing connected transactions, putting in place new 2026 Framework Agreements that will run for three years from 1 April 2026 to 31 March 2029. Among these, a logistics services agreement will see the Jacobson Group continue providing logistics services to the JBM Group, with payments in Hong Kong dollars and standard 30-day settlement terms.

Because both companies share a controlling shareholder and are deemed connected persons under Hong Kong listing rules, the renewed arrangements are classified as continuing connected transactions for each issuer. The size of the annual caps means the deals must comply with reporting, announcement and annual review requirements, but they are exempt from circular and independent shareholders’ approval, streamlining compliance while formalising ongoing intra-group operational support.

The most recent analyst rating on (HK:2633) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Jacobson Pharma Corporation Limited stock, see the HK:2633 Stock Forecast page.

More about Jacobson Pharma Corporation Limited

Jacobson Pharma Corporation Limited is a Hong Kong-listed pharmaceutical group engaged in the production, distribution and sale of generic drugs and healthcare products, with a focus on the Hong Kong and Greater China markets. JBM (Healthcare) Limited, also Hong Kong-listed, operates as a healthcare products company within the same broader corporate sphere, with both firms closely held and controlled by Mr. Sum, who is a major shareholder and key executive in each.

Average Trading Volume: 456,815

Technical Sentiment Signal: Buy

Current Market Cap: HK$2.39B

For detailed information about 2633 stock, go to TipRanks’ Stock Analysis page.